Rivaroxaban and dabigatran etexilate: Two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty

Archives of Orthopaedic and Trauma Surgery

Volumn 130, Issue 5, 2010, Pages 583-589

  Borris, Lars C ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Dabigatran etexilate; Rivaroxaban; Thromboprophylaxis; Total hip arthroplasty; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; BENZIMIDAZOLE DERIVATIVE; MORPHOLINE DERIVATIVE; PYRIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; INCIDENCE; LUNG EMBOLISM; PHARMACODYNAMICS; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; WOUND COMPLICATION; ARTICLE; ELECTIVE SURGERY; HIP ARTHROPLASTY; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; BENZIMIDAZOLES; HUMANS; MORPHOLINES; POSTOPERATIVE COMPLICATIONS; PYRIDINES; SURGICAL PROCEDURES, ELECTIVE; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 77953040108     PISSN: 09368051     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00402-009-0930-9     Document Type: Review

References (50)

1. Kurtz S, Ong K, Lau E, Mowat F, Halpern M (2007) Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 89:780-785
2. Seagroatt V, Tan HS, Goldacre M, Bulstrode C, Nugent I, Gill L (1991) Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ 303:1431-1435
3. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American College of Chest Physicians (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edn. Chest 133:381S-453S
4. Lieberman JR, Hsu WK (2005) Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 87:2097-2112
5. Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ (2005) Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost 93:76-79
6. Heit JA, Cohen AT, Anderson FA, on behalf of the VTE Impact Assessment Group (2005) Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 106:910 (abstract)
7. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M, VTE Impact Assessment Group in Europe (VITAE) (2007) Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 98:756-764
8. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG (2004) Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:338S-400S
9. Eikelboom JW, Quinlan DJ, Douketis JD (2001) Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 358:9-15
10. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31-39
11. Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA Jr (2008) Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 24:87-97
12. Warwick D, Friedman RJ, Agnelli G, Gil-Garay E, Johnson K, Fitzgerald G, Turibio FM (2007) Insuffcient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 89:799-807
13. Rahme E, Dasgupta K, Burman M, Yin H, Bernatsky S, Berry G, Nedjar H, Kahn SR (2008) Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery. CMAJ 178:1545-1554
14. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA Jr (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371:387-394
15. Dahl OE (2000) Continuing out-of-hospital prophylaxis following major orthopaedic surgery: what now? Haemostasis 30:101-105
16. Warwick D, Dahl OE, Fisher WD (2008) Orthopaedic thromboprophylaxis: limitations of current guidelines. J Bone Joint Surg Br 90:127-132
17. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J (1998) Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 158:2001-2003
18. Skedgel C, Goeree R, Pleasance S, Thompson K, O'Brien B, Anderson D (2007) The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty. J Bone Joint Surg Am 89:819-828
19. Bergqvist D, Jonsson B (1999) Cost-effectiveness of prolonged administration of a low molecular weight heparin for the prevention of deep venous thrombosis following total hip replacement. Value Health 2:288-294
20. Choay J, Lormeau JC, Petitou M, Sinay P, Fareed J (1981) Structural studies on a biologically active hexasaccharide obtained from heparin. Ann N Y Acad Sci 370:644-649
21. Bauer KA, Eriksson BI, Lassen MR, Turpie AG (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345:1305-1310
22. Eriksson BI, Bauer KA, Lassen MR, Turpie AG (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345:1298-1304
23. Lassen MR, Bauer KA, Eriksson BI, Turpie AG (2002) Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359:1715-1720
24. Turpie AG, Bauer KA, Eriksson BI, Lassen MR (2002) Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359:1721-1726
25. Turpie AG, Eriksson BI, Lassen MR, Bauer KA (2002) A metaanalysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc 11:182-188
26. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:204S-233S (Pubitemid 39297955)
27. Mismetti P, Laporte S, Zufferey P, Epinat M, Decousus H, Cucherat M (2004) Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J Thromb Haemost 2:1058-1070
28. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64:292-303
29. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949-956 (Pubitemid 47393577)
30. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR, RE-MODEL Study Group (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial. J Thromb Haemost 5:2178-2185 (Pubitemid 47617868)
31. Ginsberg J, Davidson B, Comp P, Francis CW, Friedman R, Huo M, Liberman JR, Muntz J, Raskob GE, Clements ML, Hantel S, Schnee J, Caprini JA (2008) The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24:1-9
32. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost 3:514-521
33. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78:412-421
34. Kubitza D, Becka M, Roth A, Mueck W (2008) Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 24:2757-2765
35. Xarelto® Summary of Product Characteristics (30-39-2008). Available at: http://www.xarelto.com/html/downloads/Xarelto-Summary-of-Product- Characteristics-30Sept2008.pdf. Accessed 18 May 2009
36. Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2006) No interaction between the novel, oral direct Factor Xa inhibitor BAY 59- 7939 and digoxin. J Clin Pharmacol. 46:11 (abstract)
37. Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2006) Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46:549-558
38. Kubitza D, Becka M, Mueck W, Zuehlsdorf M (2006) Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban- an oral, direct Factor Xa inhibitor-are not affected by aspirin. J Clin Pharmacol 46:981-990
39. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kalebo P, ODIXa-HIP Study Investigators (2006) A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 114:2374-2381
40. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765-2775 (Pubitemid 351930851)
41. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776-2786 (Pubitemid 351930852)
42. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673-1680
43. Lassen MR (2009) Is the preoperative administration of enoxaparin 40 mg necessary to optimally prevent the occurrence of venous thromboembolism after hip surgery? A subanalysis of two pooled randomized trials. J Thromb Haemost 7:889-891
44. Rosencher N, Bonnet MP, Sessler DI (2007) Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia 62:1154-1160
45. Pradaxa® (dabigatran etexilate); Summary of product characteristics (2008). Available at: http://www.pradaxa.com/Include/media/ pdf/Pradaxa-SPC- EMEA.pdf. Accessed 18 May 2009
46. Maezawa K, Nozawa M, Aritomi K, Kubota M, Shitoto K, Kurosawa H (2008) Changes of D-dimer after total hip arthroplasty in patients with and without intraoperative heparin. Arch Orthop Trauma Surg 128:37-40
47. Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P, BISTRO II Study Group (2005) A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 3:103-111
48. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kalebo P (2007) Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 120:685-693
49. Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kälebo P, ODIXa-HIP Study Investigators (2006) Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4:121-128
50. Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P, Misselwitz F, Gent M (2005) BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 3:2479-2486